Yumanity Therapeutics has raised a $45m Series A venture capital round, which will fund continued drug discovery related to neurodegenerative diseases caused by protein misfolding, but the company's first clinical trials probably will be financed through additional financing or potential partnership agreements.
Chairman and CEO Tony Coles, who as CEO of Onyx Pharmaceuticals sold that company to Amgen Inc. for more than...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
